11 novembre 2020, 09:52; Alessandra Losito, prima donna a capo di Pictet in Italia. "Rinviate Zurigo-Sion e Basilea-Zurigo. La manifestazione che ha riscosso maggior... Articolo completo »   Che ne pensi? », Nato in Germania, a Rheinfelden, ma di sangue irpino e oggi residente in Svizzera. basilea, news e notizie: leggi le anteprime, gli approfondimenti, le intervisite e le foto sull'argomento: basilea. », Un incendio è divampato in un magazzino del porto di Basilea: non vi sono feriti, ma i danni ammontano a diversi milioni di franchi. Il continente al centro dell'attenzione del sistema internazionale. Ultime Notizie Basilea Di seguito gli articoli di tutte le ultime Basilea news. 6 aggiornamenti sono stati effettuati durante l'ultimo minuto. Secondo il Ministero... Articolo completo »   Che ne pensi? », I lavori per Basilea 4 sono sostanzialmente conclusi. Chiusura della centrale atomica di Fessenheim, La prima gioia in Europa non si scorda mai: Petretta diventa grande col Basilea, Basilea 3: l’ennesima rivoluzione passata inosservata, Basilea: espulsa dall’aula la mamma che ha portato il figlio di 2 mesi. Questo è il bollettino di oggi 18 novembre 2020 per, Svizzera, nove positivi nello Zurigo. », Sei persone sono rimaste ferite, di cui una gravemente, ieri sera nel corso di due incidenti avvenuti quasi contemporaneamente a Basilea nell'ambito della Fiera d'autunno. intopic.it è un raccoglitore automatico di notizie dell'ultima ora di cronaca, politica e attualità italiana ed internazionale. Almeno due persone sono rimaste ferite. Le Alpi sono zona sismica Espandi le cartelle e sottocartelle per visualizzare il contenuto e selezionale per crearne di nuove all'interno. Attenzione: non è possibile salvare due documenti uguali nella stessa cartella con lo stesso titolo. Lonza raddoppia in Borsa, spinta dall'accordo con Moderna, Tecnica orologiera e lusso, Patek Philippe presenta il "Grande Sonnerie". Le Alpi sono zona sismica, Tommaso Zorzi, la scottante rivelazione su Giacomo Urtis nella notte, “Uomini e donne” oggi la sfilata, Gianni Sperti fuori controllo: «Prima faceva la putt***…» [VIDEO], Manovra 2021, Ecco le novità su lavoro e pensioni, Auto: quando la legge 104 non fa pagare il passaggio di proprietà, “Così il senatore repubblicano mi ha chiesto di invalidare i voti legali”: denuncia dalla Georgia, Calciomercato Juventus, Bernardeschi al Napoli? Basilea announces partial repurchase offer for at least CHF 90 million and up to CHF 110 million in principal amount of its outstanding convertible bonds due 2022 Read more Download Jun 24. L'incarico sarà operativo a partire dal primo gennaio, succede a Luca Toniutti che diventa presidente di Pictet Wealth Management Italy; Paolo Ramondetti diventa Deputy Head. Notizie su probabili formazioni, risultati ed ultime notizie Basilea sulle partite di campionato e tutti … », Basilea: in consiglio comunale col figlio neonato: cacciata - Succede all'assemblea municipale di Basilea Città. E la coppa Svizzera? Tutte le notizie in tempo reale solo sul sito TgCom24.it. Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. Basilea announces distribution agreement with Cardiome to commercialize antibiotic Zevtera®/Mabelio® (ceftobiprole) in Europe and Israel, Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs, Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel, Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel, Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada, Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole, Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma, Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting, Basilea names new member of its Extended Management Committee, Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders, Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections, Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab, Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors, Basilea reports solid 2016 results and expects to double product sales in 2017, Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients, Basilea's antifungal Cresemba® (isavuconazole) launched in France, Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries, Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma, Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America, Basilea starts continuous infusion phase 1/2a clinical study with oncology drug candidate BAL101553, Basilea announces distribution agreement with Hikma for CRESEMBA® (isavuconazole) in the MENA region, Basilea reports 2016 half-year results - CRESEMBA® launched in key European markets, Basilea's antifungal CRESEMBA® (isavuconazole) launched in Italy, Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting, Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting, Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program, Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Basilea issues agenda for Annual General Meeting of Shareholders, Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis, Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany, Basilea launching antifungal CRESEMBA® (isavuconazole) in the United Kingdom, Basilea reports solid 2015 full-year results and is launching CRESEMBA®, its second hospital anti-infective, in Europe, GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program, Basilea's Head of Global Human Resources, Heidi Mc Daid, to retire and Ursula Eberhardt named as successor, Basilea provides clinical program updates, Final allocations of Basilea CHF 200 million senior convertible bonds, Basilea successfully places CHF 200 million senior convertible bonds, Basilea launches a senior convertible bond issue, Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553, Basilea announces that European Commission maintained isavuconazole's orphan drug status, Basilea announces filing of registration statement for a proposed offering in the United States, Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union, Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC, Basilea announces that Health Canada approved ZEVTERA® for the treatment of bacterial lung infections, Basilea announces development of inhaled dosage form of its Gram-negative antibiotic BAL30072 as part of European iABC program, Basilea's Chief Technology Officer Dr. Ingrid Heinze-Krauss to retire and Dr. Günter Ditzinger named as successor, Basilea reports 2015 half-year results - Major milestones achieved for CRESEMBA® and Zevtera®, Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of lung and skin infections, Basilea reports topline results of isavuconazole phase 3 study in candidemia and other invasive Candida infections, Basilea announces that CHMP recommends approval of isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union, Basilea initiates phase 1/2a oncology study with oral formulation of tumor checkpoint controller BAL101553, Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor, Basilea reports isavuconazole and ceftobiprole data to be presented at ECCMID, Basilea in-licenses targeted cancer therapy, Basilea reports U.S. FDA approval of isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis, Basilea reports solid 2014 full-year results, preparing the ground for commercialization of Zevtera® in Europe, Basilea announces that FDA's Anti-Infective Drugs Advisory Committee recommends approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis, Swissmedic approves Basilea's antibiotic Zevtera® (ceftobiprole medocaril) for the treatment of pneumonia, Basilea announces launch of antibiotic Zevtera® (ceftobiprole medocaril) in Germany, Basilea reports that U.S. FDA sets date of Advisory Committee meeting on isavuconazole NDA for the treatment of invasive aspergillosis and mucormycosis, Basilea's oncology drug candidate BAL101553 induces significant anti-tumor effect in treatment-refractory tumor models, Basilea reports granting of U.S. orphan drug designation to isavuconazole for the treatment of invasive candidiasis, Basilea reports protocol amendment resulting in earlier completion of isavuconazole phase 3 invasive candidiasis study, Basilea reports that further subgroup and health economic analyses of isavuconazole phase 3 studies will be presented at IDWeek conference, Basilea's partner Astellas receives notification from U.S. FDA of acceptance of filing of isavuconazole NDA for the treatment of invasive aspergillosis and invasive mucormycosis, Extensive data presented on Basilea's anti-infectives isavuconazole, ceftobiprole and BAL30072 at ICAAC, European Medicines Agency accepts Basilea's isavuconazole Marketing Authorization Application for review, Basilea appoints Chief Commercial Officer, Basilea reports 2014 half-year financials - ceftobiprole launch in Germany planned for second half of 2014, Basilea to launch Zevtera®/Mabelio® (ceftobiprole medocaril) in Europe through a commercial services provider, Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections, Basilea reports that isavuconazole received QIDP designation from U.S. FDA for the treatment of invasive candidiasis, Basilea reports that isavuconazole receives orphan drug designations in Europe for the treatment of invasive mold infections, Basilea's partner Astellas submits isavuconazole U.S. NDA for the treatment of invasive aspergillosis and invasive mucormycosis, Basilea announces start of phase 2a study with oncology drug candidate BAL101553, Basilea provides update on ceftobiprole's U.S. regulatory status, Basilea initiates phase 1 combination study with its Gram-negative antibiotic BAL30072 and meropenem, Basilea's oncology drug candidate BAL101553 shows first evidence of antitumor activity in phase 1 study, Basilea reports additional data on positive isavuconazole phase 3 SECURE study at ECCMID, Basilea presents new data on its antibiotics pipeline at ECCMID. info_basilea@basilea.com, Basilea announces approval of antibiotic Zevtera® in China to treat community-acquired pneumonia and hospital-acquired pneumonia, Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ramucirumab in the ongoing FIDES-03 study with derazantinib in gastric cancer, Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 2020, Basilea reports interim results from phase 1/2 study FIDES-02 exploring derazantinib in patients with advanced urothelial cancer, Basilea reports pooled efficacy data for derazantinib in iCCA patients with FGFR2 gene mutations and amplifications presented at ESMO MAP Virtual Congress 2020, Basilea initiates targeted biomarker-driven phase 2 study with lisavanbulin in patients with brain cancer, Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer, Basilea reports data from poster presentations at ESMO Virtual Congress 2020, Basilea reports strong financial results for half-year 2020, progress in R&D portfolio and successful completion of strategic projects, despite COVID-19, Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (Cresemba®) in China, Basilea announces completion of its transaction involving a partial repurchase of its existing bond and the issuance of a new bond, Basilea announces data presentations at ESMO Virtual Congress 2020, Basilea announces a conversion price of CHF 62.50 for its New Bonds and the acceptance of tendered Bonds in an aggregated principal amount of approximately CHF 47 million, Basilea announces completion of patient enrolment into first cohort of phase 2 study FIDES-01 with derazantinib in bile duct cancer (iCCA), Basilea continues with the implementation of the Repurchase Offer and the issuance of New Bonds, Basilea Bonds tendered in an aggregate principal amount of approximately CHF 47 million, Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Taiwan, triggering the second milestone payment related to Asia-Pacific, Basilea announces the start of the offer period of its partial repurchase offer for its outstanding convertible bonds due 2022, Basilea announces move of corporate headquarters to Allschwil, canton of Basel-Landschaft, in 2022, Basilea announces partial repurchase offer for at least CHF 90 million and up to CHF 110 million in principal amount of its outstanding convertible bonds due 2022, Basilea successfully places CHF 125 million senior convertible bonds, Basilea launches the placement of CHF 100 million senior convertible bonds with an increase option of CHF 25 million, Basilea enters into sale and leaseback agreement for corporate headquarters building, Basilea receives CHF 5 million milestone payment related to marketing authorization of antifungal Cresemba® in Russia, Basilea announces appointment of new Head of Global Quality Management, Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting, Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Australia triggering the first milestone payment related to Asia-Pacific, Basilea reports significant revenue growth from marketed products and pipeline progress for full-year 2019, Basilea reports activity of derazantinib in preclinical models of gastric cancer at ASCO Gastrointestinal Cancers Symposium, Basilea announces clinical supply agreement for its planned study FIDES-03 with derazantinib in gastric cancer, Basilea reports total revenue exceeding guidance driven by higher than expected contributions from Cresemba® and Zevtera® in 2019, Basilea at the 38th Annual J. P. Morgan Healthcare Conference – significant progress in Cresemba commercialization and R&D portfolio in 2019, Basilea plans progression of oncology candidate lisavanbulin to targeted, biomarker-driven phase 2 study, Continued strong Cresemba® (isavuconazole) sales trigger second sales milestone this year from Pfizer to Basilea of USD 7 million, Basilea reports positive preclinical data on oncology drug candidates derazantinib and lisavanbulin at AACR-NCI-EORTC conference, Basilea reports marketing authorization of antifungal Cresemba® in Brazil, Basilea reports at ESMO meeting that drug candidate derazantinib showed clinical benefit in intrahepatic cholangiocarcinoma (iCCA) patients with various FGFR2 genetic aberrations, Basilea announces completion of patient enrolment in phase 1 study with oral BAL101553 in brain cancer, Basilea reports significantly increased cash-generating revenue, flat operating expenses and reduced net loss for half-year 2019, Basilea starts phase 1/2 study with derazantinib in urothelial cancer, Basilea announces positive results of phase 3 TARGET study with antibiotic ceftobiprole in the treatment of acute bacterial skin and skin structure infections (ABSSSI), Basilea extends phase 2 study with derazantinib in intrahepatic bile duct cancer (iCCA) to include patients with FGFR2 gene mutations or amplifications, Basilea reports publication of clinical data for anticancer drug candidates BAL101553 in glioblastoma and derazantinib in intrahepatic cholangiocarcinoma at ASCO meeting, Basilea's partner Avir Pharma has launched antifungal Cresemba® (isavuconazole) in Canada, Basilea reports isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Basilea reports strong revenue growth and significant pipeline progress for full-year 2018, Strong European Cresemba® (isavuconazole) sales trigger USD 5 million milestone payment to Basilea from Pfizer, Basilea announces change in the Management Committee - Adesh Kaul appointed CFO, Basilea announces collaboration to study derazantinib and atezolizumab (Tecentriq®) in urothelial cancer, Basilea reports positive interim results from registrational phase 2 study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma (iCCA), Basilea reports strong, higher than expected preliminary revenue of CHF 133 million for financial year 2018, Basilea presenting at the 37th Annual J. P. Morgan Healthcare Conference - delivering on its strategy, Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea, Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium, Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline, Basilea reports on first Cresemba® approval in MENA region, Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB), Basilea reports receipt of milestone payment based on first Cresemba® approval in Latin America, Basilea starts clinical phase 2a expansion with BAL101553 in ovarian cancer and glioblastoma, Basilea reports presentation of phase 1 clinical data with anticancer drug candidate BAL101553 at ASCO meeting, Basilea Pharmaceutica: Subscription to Basilea's Press Release Newsletter, Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC, Basilea announces appointment of Chief Technology Officer and appointment of Head of Global Quality Management, Basilea reports presentations of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting of Shareholders, Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole, Basilea licenses late-stage oncology drug candidate derazantinib from ArQule, Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma, Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana, Basilea names Adesh Kaul as new member of its Management Committee, Basilea reports significantly improved financial results in 2017, Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract, Basilea's CEO Ronald Scott will retire.